| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 137 | 155 | 159 | 180 | 166 | 179 | 185 | 178 | 175 | 203 | 209 | 221 | 223 | 237 | 238 | 266 | 254 | 284 | 300 | 316 | 335 | 352 | 357 | 393 | 402 | 447 | 448 | 467 | 447 | 479 |
| Expenses | 103 | 116 | 125 | 139 | 125 | 132 | 135 | 131 | 125 | 143 | 146 | 159 | 157 | 173 | 179 | 202 | 202 | 210 | 214 | 224 | 234 | 253 | 249 | 282 | 281 | 305 | 310 | 321 | 298 | 329 |
| EBITDA | 35 | 39 | 35 | 41 | 41 | 47 | 50 | 47 | 50 | 60 | 63 | 63 | 66 | 64 | 59 | 64 | 51 | 74 | 86 | 92 | 101 | 99 | 108 | 112 | 121 | 142 | 138 | 146 | 149 | 150 |
| Operating Profit % | 23 % | 23 % | 20 % | 20 % | 23 % | 24 % | 25 % | 23 % | 27 % | 28 % | 28 % | 25 % | 26 % | 23 % | 22 % | 22 % | 19 % | 24 % | 25 % | 27 % | 27 % | 25 % | 27 % | 26 % | 27 % | 27 % | 27 % | 27 % | 26 % | 26 % |
| Depreciation | 9 | 9 | 10 | 10 | 10 | 10 | 11 | 10 | 11 | 11 | 13 | 13 | 13 | 14 | 14 | 14 | 14 | 14 | 14 | 15 | 16 | 16 | 16 | 16 | 20 | 21 | 22 | 21 | 23 | 25 |
| Interest | 4 | 7 | -1 | 2 | 3 | 2 | 5 | 8 | 3 | 3 | 5 | -2 | 3 | 0 | -1 | 2 | 1 | 0 | 5 | 2 | 3 | 2 | 4 | 3 | 3 | 3 | 3 | 2 | 3 | 3 |
| Profit Before Tax | 22 | 23 | 26 | 30 | 28 | 36 | 34 | 29 | 36 | 46 | 46 | 52 | 50 | 50 | 46 | 49 | 36 | 59 | 67 | 75 | 83 | 81 | 88 | 93 | 99 | 118 | 113 | 123 | 123 | 122 |
| Tax | 9 | 9 | 10 | 8 | 8 | 7 | 9 | 6 | 10 | 11 | 11 | 13 | 13 | 12 | 11 | 13 | 9 | 16 | 17 | 16 | 20 | 19 | 23 | 24 | 24 | 31 | 28 | 31 | 30 | 30 |
| Net Profit | 13 | 15 | 16 | 22 | 20 | 28 | 25 | 23 | 27 | 35 | 35 | 39 | 38 | 38 | 35 | 36 | 27 | 44 | 50 | 59 | 63 | 62 | 65 | 68 | 74 | 87 | 85 | 92 | 93 | 92 |
| EPS in ₹ | 1.50 | 1.65 | 1.82 | 2.44 | 2.24 | 3.22 | 2.83 | 2.57 | 3.03 | 3.97 | 4.00 | 4.26 | 3.92 | 3.99 | 3.60 | 3.77 | 2.81 | 4.53 | 5.21 | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | 9.01 | 8.48 | 8.92 | 9.19 | 9.06 |
Poly Medicure
Poly Medicure
1,932.00
-7.10
(-0.37%)
Market Cap
₹19,576.13 Cr
PE Ratio
52.70
Volume
44,758.00
Day High - Low
₹1,952.30 - ₹1,920.00
52W High-Low
₹3,031.00 - ₹1,821.20
Key Fundamentals
Market Cap
19,576.13 Cr
EPS
34.13
PB Ratio
6.54
Book Value
287.92
EBITDA
542.00
Dividend Yield
0.19 %
Industry
Healthcare Sector
Medical Equipment ROE Growth %
-
Debt to Equity
0.08
Analyst Rating and Forecast
- By Refinitiv from5 analysts
Actual
Company News
View All News
PolyMedicure Reports 5.7% Revenue Growth, Completes Two Strategic Acquisitions Worth Rs 280 Crores
Nov 14, 2025
Nov 14, 2025PolyMedicure achieved consolidated revenue of Rs 444 crores in Q2 FY26 with 5.7% year-on-year growth, while completing acquisitions of Italy-based Citieffe Group and Netherlands-based Pendra Care Group. The company guided for H2 revenue of Rs 1,080-1,090 crores (25% increase over H1) and maintained operating EBITDA margin guidance of 25-27%, despite facing headwinds in European markets and US tariff challenges.
PolyMedicure Limited submitted its monitoring agency report for the quarter ended September 30, 2025, showing utilization of proceeds from its Qualified Institutional Placement (QIP) issue. The company raised Rs 99,999.98 lakh through the QIP conducted from August 19-22, 2024, with net proceeds of Rs 98,534.37 lakh. During the reported quarter, the company completed a significant acquisition through its step-down subsidiary RisoR Holdings B.V., acquiring the entire share capital of Pendra Care Group (comprising Pendracare Holdings B.V. and Welling Medical B.V.) for approximately Rs 15,163.32 lakh. Of this acquisition cost, Rs 15,093.34 lakh was funded from QIP proceeds. The QIP proceeds are allocated across three objectives: Rs 49,973.16 lakh for setting up manufacturing facilities, Rs 25,026.84 lakh for pursuing inorganic initiatives, and Rs 23,534.37 lakh for general corporate purposes. CRISIL Ratings Limited, the monitoring agency, reported no deviations from the stated objectives and confirmed all utilization was as per the placement document.
Poly Medicure has lowered its revenue growth forecast for FY26 to 15-16%, down from its previous target of 20%. The company has revised its growth expectations downward by approximately 4-5 percentage points.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,932.00 | #1 19,576.13 | #5 52.70 | #1 1,759.00 | #7 22.62 | #1 339 | #2 5.03 | 50.34 | |
271.30 | 1,491.12 | 62.45 | 242.40 | 24.12 | 25 | 44.07 | 27.59 | |
770.35 | 1,363.10 | 70.93 | 186.60 | 40.62 | 20 | - | 62.44 | |
230.18 | 1,224.70 | 57.09 | 408.40 | 32.64 | 30 | -67.96 | 36.75 | |
229.71 | 1,021.08 | #1 22.88 | 326.67 | 41.78 | 46 | 751.52 | 50.31 | |
600.00 | 997.30 | 67.58 | 249.37 | 43.89 | 17 | -14.81 | 51.54 | |
332.95 | 633.94 | 41.70 | 136.30 | #1 107.77 | 16 | 50.00 | 62.38 | |
445.00 | 558.60 | 28.18 | 67.10 | 13.15 | 18 | 14.58 | 31.82 | |
271.95 | 390.18 | 46.19 | 111.80 | -1.43 | 8 | 0.00 | 43.64 | |
297.55 | 297.56 | 63.49 | 122.10 | 19.24 | 1 | #1 820.00 | 64.62 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
22.62 %
Net Income Growth
31.09 %
Cash Flow Change
-9.64 %
ROE
-30.34 %
ROCE
-30.22 %
EBITDA Margin (Avg.)
6.13 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,193 |
| Fixed Assets | 166 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 |
| Current Assets | 160 | 171 | 205 | 255 | 302 | 318 | 704 | 783 | 807 | 842 | 1,917 |
| Capital Work in Progress | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 |
| Investments | 0 | 0 | 3 | 17 | 8 | 25 | 354 | 346 | 126 | 167 | 1,077 |
| Other Assets | 189 | 191 | 227 | 264 | 321 | 354 | 422 | 499 | 738 | 749 | 930 |
| Total Liabilities | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,193 |
| Current Liabilities | 113 | 109 | 114 | 123 | 154 | 197 | 171 | 227 | 293 | 351 | 370 |
| Non Current Liabilities | 55 | 50 | 72 | 104 | 119 | 135 | 87 | 63 | 42 | 37 | 57 |
| Total Equity | 196 | 229 | 272 | 338 | 381 | 435 | 966 | 1,088 | 1,242 | 1,470 | 2,766 |
| Reserve & Surplus | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 |
| Share Capital | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 | -3 |
| Investing Activities | -59 | -31 | -56 | -88 | -101 | -110 | -436 | -85 | -179 | -241 | -1,194 |
| Operating Activities | 63 | 63 | 56 | 75 | 107 | 131 | 119 | 124 | 191 | 266 | 240 |
| Financing Activities | -6 | -31 | -0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 | 951 |
Share Holding
| % Holding | Feb 2021 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Aug 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 44.88 % | 44.88 % | 44.77 % | 44.77 % | 44.76 % | 44.66 % | 53.34 % | 53.33 % | 53.33 % | 53.31 % | 53.31 % | 53.16 % | 53.16 % | 53.15 % | 66.03 % | 62.56 % | 62.56 % | 62.44 % | 62.44 % | 62.44 % | 62.42 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.49 % | 0.00 % | 12.38 % | 9.91 % | 11.10 % | 11.87 % | 12.33 % | 11.46 % | 11.41 % | 9.77 % |
| DIIs | 1.83 % | 1.92 % | 2.68 % | 2.73 % | 2.86 % | 3.18 % | 3.10 % | 3.20 % | 3.38 % | 3.68 % | 4.25 % | 5.15 % | 5.28 % | 7.22 % | 9.35 % | 12.48 % | 12.33 % | 11.66 % | 11.96 % | 11.72 % | 13.54 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 15.11 % | 14.24 % | 13.69 % | 13.24 % | 12.32 % | 11.93 % | 11.20 % | 11.18 % | 11.12 % | 11.10 % | 11.35 % | 11.38 % | 11.34 % | 11.37 % | 10.70 % | 10.14 % | 10.55 % | 11.08 % | 11.37 % | 11.25 % |
| Others | 37.06 % | 38.10 % | 38.30 % | 38.81 % | 39.14 % | 39.84 % | 31.63 % | 32.27 % | 32.11 % | 31.90 % | 31.34 % | 15.85 % | 30.17 % | 15.92 % | 3.36 % | 3.16 % | 3.10 % | 3.03 % | 3.07 % | 3.07 % | 3.02 % |
| No of Share Holders | 0 | 19,187 | 21,531 | 35,922 | 33,678 | 35,166 | 33,831 | 33,296 | 34,239 | 35,393 | 36,141 | 34,649 | 36,053 | 36,712 | 36,852 | 40,516 | 38,352 | 60,686 | 65,583 | 71,142 | 64,400 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2.5 | 2 | 2 | 2 | 2.5 | 2.5 | 3 | 3 | 3.5 |
| Dividend Yield (%) | 0.00 | 1 | 0.91 | 0.86 | 0.24 | 0.26 | 0.27 | 0.19 | 0.13 | 0.18 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Mar 2017 |  Bonus | 1:1 | 24 Mar 2017 | 0.00 | 0.00 |
| 17 Sept 2021 |  Dividend | ₹ 2.50 /share | 16 Sept 2021 | 1,133.15 | 955.00 |
| 19 Sept 2022 | Dividend | ₹ 2.50 /share | 16 Sept 2022 | 715.55 | 933.00 |
| 22 Sept 2023 | Dividend | ₹ 3.00 /share | 21 Sept 2023 | 977.25 | 1,413.65 |
| 20 Sept 2024 | Dividend | ₹ 3.00 /share | 19 Sept 2024 | 1,654.70 | 2,462.65 |
| 26 Sept 2024 |  Annual General Meeting | NA | 26 Sept 2024 | 2,498.45 | 2,318.00 |
| 28 Oct 2024 |  Quarterly Result Announcement | NA | 28 Oct 2024 | 2,450.95 | 2,514.10 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 2,445.25 | 2,433.90 |
| 06 May 2025 | Quarterly Result Announcement | NA | 06 May 2025 | 2,587.85 | 2,584.60 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 2,057.40 | 1,931.65 |
| 18 Sept 2025 | Dividend | ₹ 3.50 /share | 18 Sept 2025 | 2,584.60 | 1,996.60 |
| 25 Sept 2025 | Annual General Meeting | NA | 25 Sept 2025 | 2,067.00 | 1,981.35 |
| 08 Nov 2025 | Quarterly Result Announcement | NA | 08 Nov 2025 | 1,974.45 | 1,893.80 |
Announcements
Intimation Of Investors/Analyst Virtual Calls9 days ago
9 days agoIntimation Of Investors/Analyst Virtual Call On 24Th November 2025Nov 20, 2025
Nov 20, 2025Intimation Of Investotrs/Analyst Virtual Call On 24Th November 2025Nov 19, 2025
Nov 19, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 14, 2025
Nov 14, 2025Statement Of Deviation & Variation For The Quarter Ended 30Th September 2025Nov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 12, 2025
Nov 12, 2025Investor/Analyst CallsNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 10, 2025
Nov 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 10, 2025
Nov 10, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 08, 2025
Nov 08, 2025Declaration Of Unaudited Financial Results For The Second Quarter And Half Year Ended For 30Th September 2025.Nov 08, 2025
Nov 08, 2025Board Meeting Outcome for Outcome Of Board Meeting Held Hold Today I.E. 08Th November 2025 For Declaration Of Unaudited Financial Results(Standalone & Consolidated) For The Second Quarter And Half Year Ended 30Th September 2025 And For Other Businesses ItNov 08, 2025
Nov 08, 2025 Announcement Under Regulation 30 (LODR)-Updates On AcquisitionNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Nov 05, 2025Board Meeting Intimation for Notice Of Board Meeting To Be Held On 08Th November 2025.Oct 31, 2025
Oct 31, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Transcript Of Investors/Analysts Conference Call Held On 25Th September 2025.Oct 01, 2025
Oct 01, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 27, 2025
Sep 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeSep 25, 2025
Sep 25, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Investor PresentationSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Sep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 24, 2025
Sep 24, 2025Outcome Of Board Meeting Held On Today I.E. 24Th September 2025 - Updates On Share Purchase Agreement For Acquisition Purpose Of "Citieffe Group"Sep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 23, 2025
Sep 23, 2025Intimation For Cancellation Investor/Analyst Meet Scheduled To Be Held On Today I.E. 19.09.2025Sep 19, 2025
Sep 19, 2025Intimation Of Investor/Analyst Call Scheduled To Be Held On Friday 19Th September 2025Sep 17, 2025
Sep 17, 2025Revised Intimation For The Investors/Analyst One To One Virtual Call Scheduled To Be Held On Tuesday 16Th September 2025Sep 12, 2025
Sep 12, 2025Intimation Of Investor/Analyst One To One Virtual Meeting To Be Held On Tuesday 16Th September 2025Sep 12, 2025
Sep 12, 2025Intimation For The Analyst/Investor Call As On 11Th September 2025.Sep 09, 2025
Sep 09, 2025Tranascript Of Investor/Analyst Conference Call Held On 04Th September 2025.Sep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesSep 05, 2025
Sep 05, 2025Book Closure For The Purpose Of Record Date For The Purpose Of DividendSep 05, 2025
Sep 05, 2025Record Date/Cut-Off Date For The Dividend PurposeSep 05, 2025
Sep 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 04, 2025
Sep 04, 2025Intimation For Signing Of Share Purchase Agreement (SPA) Between Risor Holdings B.V. Amsterdam Netherlands A Wholly Owned Step-Down Subsidiary Of The Company With Wellinq Holdings B.V. Amsterdam Netherlands.Sep 04, 2025
Sep 04, 2025Intimation Of Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company Or DepositoriesSep 03, 2025
Sep 03, 2025Business Responsibility and Sustainability Reporting (BRSR)Sep 03, 2025
Sep 03, 2025Reg. 34 (1) Annual Report.Sep 03, 2025
Sep 03, 202530Th Annual General Meeting To Be Held On Thursday September 25 2025.Sep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Investor PresentationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-AcquisitionSep 03, 2025
Sep 03, 2025Outcome Of Board Meeting_Acquisition(Incorporation Of A Wholly Owned Step Down Subsidiary "Risor Holdings B.V." In Amsterdam Netherlands And Updates On The Share Purchase Agreements (SPA)Sep 03, 2025
Sep 03, 2025Mutual Fund Holdings
Bank of India ELSS Tax Saver Direct-Growth 
Invesco India Largecap Fund Direct-Growth 
UTI Flexi Cap Fund Direct-Growth 
Bandhan Small Cap Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
Quant Small Cap Fund Direct Plan-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
SBI Nifty 500 Index Fund Direct-Growth 
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth 
Kotak Nifty Smallcap 250 Index Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 51.15
ATR(14)
Less Volatile 62.37
STOCH(9,6)
Neutral 33.76
STOCH RSI(14)
Neutral 43.29
MACD(12,26)
Bullish 1.78
ADX(14)
Weak Trend 16.82
UO(9)
Bearish 46.91
ROC(12)
Downtrend And Accelerating -4.26
WillR(14)
Neutral -62.51
About Poly Medicure
Poly Medicure Limited is an Indian medical device manufacturer founded in 1995. The company produces over 130 SKUs of medical devices across various product verticals including infusion therapy, oncology, anesthesia, respiratory care, urology, gastroenterology, blood management, surgery, and dialysis. Poly Medicure operates ten manufacturing facilities across India, China, Egypt, and Italy, with seven in India, one in China through a wholly-owned subsidiary, one in Egypt through an associate, and one in Italy through a step-down subsidiary. The company exports to over 110 countries through a network of more than 220 distributors. Poly Medicure's facilities are accredited with international quality certifications, including ISO 9001:2015 and EN ISO 13485:2016. The company has an R&D center in Faridabad, Haryana, approved by DSIR, focusing on developing new products and improving existing processes. Poly Medicure holds over 375 patents for its products in various therapeutic areas.
Website
Chairperson NameDevendra Raj Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
